Quick overview of the latest price of dacomitinib/dacomitinib in 2024

Dacomitinib/Dacomitinib (Dacomitinib) is a targeted therapy drug designed specifically for patients with non-small cell lung cancer (NSCLC). It effectively inhibits the growth and spread of tumor cells by precisely inhibiting the kinase activity of the epidermal growth factor receptor (EGFR). In particular, this drug has a significant effect on patients with locally advanced or metastatic non-small cell lung cancer who have EGFR exon 19 deletion or exon 21 L858R mutation.

In the treatment of non-small cell lung cancer, dacomitinib has consolidated its position as a first-line treatment drug with its excellent disease control and survival prolongation effects. However, patients need to remain alert to possible adverse reactions such as interstitial pneumonia and diarrhea during medication, and strictly follow medical instructions for treatment.

What is gratifying is that this important original drug has been launched in China and has been included in Class B medical insurance, which has greatly reduced the financial burden on patients. Currently, the price of 15 mg × 30 tablets in the domestic market is about more than 1,000 yuan, allowing more patients to enjoy this advanced treatment. However, in overseas markets, especially in the European market, the price of 45 mg × 30 tablets is as high as more than 20,000 yuan. Of course, this price will be adjusted according to changes in exchange rates.

It is worth mentioning that there are also extremely cost-effective drug options in overseas markets. For example, each box of dacomitinib generic drug produced in Laos contains 45 mg × 30 tablets, and the price is only about 800 yuan. This is undoubtedly an economical and affordable option for patients who require long-term medication. However, its price may also change due to exchange rate fluctuations.